Patents Examined by F. T. Moezie
  • Patent number: 6514759
    Abstract: The present invention relates to a peptide of the formula: wherein R1 and R2 are the same or different and each represents SO3H or H; X represents an &agr;-amino acid or a single bond; Z1 and Z2 are the same or different and each represents an &agr;-amino acid; and Y represents OH or NH2. This peptide has plant growth factor properties.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: February 4, 2003
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Youji Sakagami, Yoshikatsu Matsubayashi
  • Patent number: 6479523
    Abstract: Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: November 12, 2002
    Assignee: Emory University
    Inventor: John D. Puskas
  • Patent number: 6410694
    Abstract: A method for the solubilization and/or naturation of a somatotropin involves contacting a somatotropin with a detergent composition and water under conditions effective to obtain a naturated somatotropin, wherein the detergent composition may be a C10, C12, C16 or C18 acyl glutamate, a C10, C14 or C18 alkyl sulfate, an alcohol ethoxy sulfate, lauroyl ethylenediamine-triacetic acid (LEDA), a C10 to C18 linear alkyl benzene sulfonate, diphenyl disulfonate or an acyl amino acid.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: June 25, 2002
    Assignee: Monsanto Technology LLC
    Inventors: S. Bradley Storrs, Jacob S. Tou, Jessica Marie Ballinger
  • Patent number: 6388054
    Abstract: The present invention provides compounds useful to inhibit tumor growth and to induce apoptosis. In general, the anti-cancer agents (ACA) are described by the formula: [ACA]n-X  [Formula I] wherein X is a linker group having 2-5 functional groups or is absent, n=1, and ACA is selected from the group consisting of Formula II, Formula III, Formula IV, Formula V, and Formula VI, as described herein. Other compounds described herein are defined by the Formula VII, as described herein.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: May 14, 2002
    Inventors: John M. Stewart, Daniel C. F. Chan, Lajos Gera, Eunice York, Paul Bunn
  • Patent number: 6358921
    Abstract: The invention concerns antimicrobial cyclic peptides and peptide analogs having relatively low hemolytic activity. Peptides of the invention are effective in killing and/or inhibiting growth of a number of microorganisms, including gram-positive bacteria, gram-negative bacteria, fungi and mycoplasma. Also disclosed are methods for inhibiting or killing such microorganisms, and therapeutic preparations for such inhibiting or killing.
    Type: Grant
    Filed: October 10, 1997
    Date of Patent: March 19, 2002
    Assignee: Pence, Inc.
    Inventors: Leslie H. Kondejewski, Robert S. Hodges, David S. Wishart, Robert E. W. Hancock, Ronald N. McElhaney, Elmar J. Prenner, Ruthven N. A. H. Lewis
  • Patent number: 6352997
    Abstract: The present invention provides for a method of treating polycystic ovary syndrome in a subject in need of such treatment comprising the administration of a therapeutically effective amount of a compound of structural formula I: to the subject. The present invention further provides for a method for improving fertility and the response to in vitro fertilization (I.V.F.), comprising administration of therapeutically effective amount of compound of structural formula I to the subject. Further, the present invention provides for compositions useful in the methods of the present invention, as well as a method of manufacture of a medicament useful for treating polycystic ovary syndrome or for improving fertility or the response to in vitro fertilization (I.V.F.).
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 5, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Joanne Waldstreicher, Georgianna S. Harris
  • Patent number: 6352974
    Abstract: The present invention relates to novel compositions, in particular to compositions comprising calcitonin or a fragment or conjugate thereof and to methods for preparing such compositions. It also relates to oral formulations comprising the compositions and to shelf stable formulations of calcitonin or a fragment or conjugate thereof.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: March 5, 2002
    Assignee: Eurand International S.p.A.
    Inventors: Matteo Ghirri, Marco Zema
  • Patent number: 6350430
    Abstract: The invention provides ligands for melanocortin receptors. For example, the invention provides the melanocortin receptor peptide ligand Ac-Nlc-Gln-His-(p(I)-D-Phe)-Arg-(D-Trp)-Cly-NH2, (SEQ ID NO: 1), where the iodo group is unlabeled or radioactively labeled. The invention additionally provides methods of assaying for melanocortin receptors in a cell or tissue such as brain. The invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a melanocortin receptor ligand and to methods of administering the pharmaceutical composition to a subject. The invention further provides tetrapeptide ligands for melanocortin receptors and methods of altering melanocortin receptor activity.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: February 26, 2002
    Assignee: Lion Bioscience Science AG
    Inventors: Colette T. Dooley, Beverly E. Girten, Richard A. Houghten
  • Patent number: 6346512
    Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: February 12, 2002
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6342477
    Abstract: Agents for preventing and treating thrombocytopenia, thrombocytopenic purpura and various diseases that tend to cause bleeding due, presumably, to thrombocytopenia contain a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: January 29, 2002
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masahiko Tamura, Yasuhiro Oda
  • Patent number: 6337318
    Abstract: A pharmaceutical and/or veterinary formulation for sustained release of a peptide agonist or analogue, comprising about 2-15% (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5% (w/w) lecithin and the balance stearin. The formulation preferably comprises a GnRH agonist or analogue and is used for the treatment of various conditions where suppression of sex hormone levels is beneficial, particularly prostate cancer, ovarian and breast cancer, and benign prostatic hyperplasia in dogs.
    Type: Grant
    Filed: February 19, 1999
    Date of Patent: January 8, 2002
    Assignee: Peptech, Ltd.
    Inventors: Timothy Elliot Trigg, John Desmond Walsh, Paul Adam Schober
  • Patent number: 6335317
    Abstract: The present disclosure describes methods for minimizing oxidative damage in an animal or human during or after malnutrition, underfeeding or fasting, especially during refeeding after undernutrition or malnutrition, and for minimizing oxidant damage during or after toxicity resulting from chemotherapy, alcoholism, irradiation therapy or chemical or environmental exposure to a toxic compound. Administration of an effective amount of a gut trophic growth factor (GTGF) effective for improving gut and/or systemic antioxidant status results in improved clinical condition and/or outcome for the patient or animal to which the GTGF has been administered. In the context of the present disclosure, GTGF includes fibroblast growth factors, keratinocyte growth factor, hepatocyte growth factor, insulin-like growth factor I, glucagon, glicentin, and glucagon-like peptide.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: January 1, 2002
    Assignee: Emory University
    Inventors: Thomas R. Ziegler, Dean P. Jones
  • Patent number: 6333307
    Abstract: Modulating agents comprising cyclic peptides, and compositions comprising such modulating agents are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating and/or directing neurite outgrowth in a variety of contexts are also provided.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: December 25, 2001
    Assignee: McGill University
    Inventors: Orest W. Blaschuk, Barbara J. Gour
  • Patent number: 6331520
    Abstract: Pharmaceutical compositions are described, which comprise: a) a peptide poorly soluble in aqueous physiological saline solution, as active ingredient; b) a non-ionic aromatic hydrotropic pharmaceutically acceptable agent; and c) a physiological aqueous solution.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: December 18, 2001
    Assignee: Applied Research Systems ARS Holding NV
    Inventor: Peter Richardson
  • Patent number: 6306822
    Abstract: Phosphopeptides which significantly reduce bone loss or weakening are provided by the invention. Also provided is a method for treating or preventing any condition associated with bone loss or weakening by administering the phosphopeptides by oral or injectable means.
    Type: Grant
    Filed: November 16, 1998
    Date of Patent: October 23, 2001
    Assignee: Big Bear Bio, Inc.
    Inventors: Yoshinari Kumagai, Akira Otaka
  • Patent number: 6306450
    Abstract: Storage-stable, citrus-flavored compositions comprising citral or a citral derivative as the flavoring agent and a plant extract as the stabilizing agent. The plant extract inhibits the formation of p-methylacetophenone, thereby preventing the development of off-flavors and off odors, and increasing the shelf life of the composition.
    Type: Grant
    Filed: June 23, 1998
    Date of Patent: October 23, 2001
    Assignee: Hauser, Inc.
    Inventors: Virginia R. Bank, David T. Bailey, Johan T. van Leersum
  • Patent number: 6297354
    Abstract: The present invention relates to a class of pentapeptide analogs of LHRH. These compounds are useful in the treatment of disease conditions which are mediated by reproductive hormones, including benign prostate hyperplasia, prostate tumors, breast and ovaries tumors, cryptorchidism, hirsuitism, gastric motility disorders, dysmenorrhea, and endometriosis.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: October 2, 2001
    Assignee: Abbott Laboratories
    Inventors: Fortuna Haviv, Wesley Dwight, Jonathan Greer
  • Patent number: 6268344
    Abstract: A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and other transplantations, severe burns, pregnancy, major surgery, severe trauma, or ARDS, which comprises administering activated protein C providing a highly selective therapeutic agent with a low potential for causing bleeding complications.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: July 31, 2001
    Assignee: Eli Lilly and Company
    Inventors: Brian William Grinnell, Daniel Lawrence Hartman, Sau-Chi Betty Yan
  • Patent number: 6255286
    Abstract: Depsipeptides represented by the formula (1): (wherein: R1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R2 is —A—B, —A—B—W, —A—B—W—D or —A—B—W—D—E, R3 is a hydroxyl group, a lower alkoxy group, a benzyloxy group, —Z, —Z—G or —Z—G—J, the above A, B, D, E, G and J independently each other are a residue of an amino acid selected from alanine, valine, leucine, isoleucine, serine, threonine, lysine, hydroxylysine, arginine, cysteine, methionine, phenylalanine, tyrosine, aspartic acid, asparagine, glutamic acid, glutamine and the like or an N—(C1-C4) alkyl derivative of these amino acid residues; the above W and Z independently each other are a residue of an amino acid selected from aspartic acid, asparagine, glutamic acid, glutamine, alanine, serine or lysine) or pharmacologically acceptable
    Type: Grant
    Filed: December 24, 1998
    Date of Patent: July 3, 2001
    Assignee: Nisshin Flour Milling Co., Ltd.
    Inventors: Makoto Yanai, Masashi Suzuki, Norio Oshida, Koji Kawamura, Shigeru Hiramoto, Orie Yasuda, Nobuhiro Kinoshita, Akiko Shingai, Masako Takasu
  • Patent number: 6255344
    Abstract: The invention relates to novel histidine derivatives corresponding to the general formula (I) below: in which: R denotes a linear or branched, saturated or unsaturated alkyl radical containing from 6 to 22 carbon atoms, n is an integer ranging from 1 to 16, Q+ represents H+ or an organic or inorganic cation, and the addition salts with an acid. The invention also relates to a process for preparing the compounds of formula (I), as well as to the use of these compounds in cosmetics and pharmacy.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: July 3, 2001
    Assignee: L'Oreal S.A.
    Inventors: Michel Philippe, Thierry Bordier